At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYTM Rhythm Pharmaceuticals Inc.
Market Closed 12-12 16:00:00 EST
113.56
-4.06
-3.45%
盘后113.60
+0.04+0.04%
19:55 EST
High119.58Low109.59Vol1.74M
Open119.58D1 Closing117.62Amplitude8.49%
Mkt Cap7.58BTradable Cap6.07BTotal Shares66.74M
T/O198.66MT/O Rate3.26%Tradable Shares53.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says
MT Newswires Live  ·  12-13 00:08
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating
MT Newswires Live  ·  12-12 19:53
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones  ·  12-12 02:54
Rhythm Pharmaceuticals Is Maintained at Buy by Needham
BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
Reuters  ·  12-11 22:39
BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
Rhythm Pharmaceuticals Shares up 12% After Positive Mid-Stage Data for Rare Disease Therapy
THOMSON REUTERS  ·  12-11 22:34
Rhythm Pharmaceuticals Shares up 12% After Positive Mid-Stage Data for Rare Disease Therapy
BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy
Reuters  ·  12-11 21:56
BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy
BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome
Reuters  ·  12-11 20:34
BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome
Rhythm Pharmaceuticals Inc - Plans Phase 3 Trial for Setmelanotide in Pws
THOMSON REUTERS  ·  12-11 20:30
Rhythm Pharmaceuticals Inc - Plans Phase 3 Trial for Setmelanotide in Pws
Rhythm Pharmaceuticals Inc: Safety and Tolerability Results Have Been Consistent With Setmelanotide's Well-Established Clinical Profile
THOMSON REUTERS  ·  12-11 20:30
Rhythm Pharmaceuticals Inc: Safety and Tolerability Results Have Been Consistent With Setmelanotide's Well-Established Clinical Profile
Rhythm Pharmaceuticals Announces Preliminary Phase 2 Data for Setmelanotide in Prader-Willi Syndrome
Reuters  ·  12-11
Rhythm Pharmaceuticals Announces Preliminary Phase 2 Data for Setmelanotide in Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Preliminary Data From Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
THOMSON REUTERS  ·  12-11
Rhythm Pharmaceuticals to Announce Preliminary Data From Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com
Dow Jones  ·  12-05
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com
Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating
Simply Wall St.  ·  11-29
Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating
How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story
Simply Wall St.  ·  11-27
How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story
Rhythm Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones  ·  11-25
Rhythm Pharmaceuticals Initiated at Buy by Citigroup
Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target
MT Newswires Live  ·  11-25
Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target
Rhythm Pharmaceuticals initiated with a Buy at Citi
TIPRANKS  ·  11-25
Rhythm Pharmaceuticals initiated with a Buy at Citi
Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares
Reuters  ·  11-25
Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares
S&P 500 Futures Climb In Premarket Trading; Centene, Millicom Intl Cellular Lead
Dow Jones  ·  11-24
S&P 500 Futures Climb In Premarket Trading; Centene, Millicom Intl Cellular Lead
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Reuters  ·  11-20
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Introduction

Company Name.
Rhythm Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--